SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

BOARD MEETING
Pascal Bijleveld, Nadia Lasri
6-7 June 2018, Geneva, Switzerland
Key developments since the last Board meeting

- No immediate change in macroeconomic context
- Major outbreaks, incl. MenACWY, Cholera, Yellow Fever and Lassa Fever
- Audit: 2\textsuperscript{nd} tranche paid in January 2018; 3\textsuperscript{rd} tranche, 1\textsuperscript{st} part of payment of $2.998M paid on 30\textsuperscript{th} May and the balance is being processed by CBN.
- Approval of 1\% of Nigeria’s Consolidated Revenue Fund towards Basic Health Care Provision Fund (BHCPF) in the 2018 budget
- Increased Alliance engagement, incl. High-Level Mission, strategic & technical engagement
- Nigeria Strategy for Immunisation and PHC System Strengthening 2018 – 2028 (NSIPSS)
What is the government of Nigeria doing differently?

An evidence-based and focused strategy: *Optimized Integrated Routine Immunization Sessions (OIRIS)*

*Over 4.3m children are under-immunised despite vaccines availability, mainly due to…*

- Lack of awareness
- Service Delivery issues: 27%
- Lack of time or other family issues: 42%
- Mistrust/fears: 22%
- Other issues: 9%

In addition…

- High-level leadership & commitment
- Recognition and acceptance of short-comings
- Focus on accountability
- NPHCDA reforms, including NERICC & SERICC approach
- Increased partner engagement and alignment
- Increased tailoring & targeting, with mechanisms for course correction
With Gavi support, Nigeria is aiming to achieve an ambitious target of 84% Penta3 coverage by 2028.

Potential new introductions:

- MenA (Q1/Q2 2019)
- Rota (Phased, starting Q4 2019)
- Measles 2\textsuperscript{nd} dose (Q4 2019)
- HPV (2020/2021)
Gavi to support an additional US$461M in vaccine financing*

Gavi’s total vaccine support is US$773M from 2018-2028
The government co-financing will be US$1.9B

* Assuming planned new introductions take place, pending progress on coverage and co-financing
Additional Gavi support of US$ 160M to achieve greater coverage and equity, total of up to US$ 260M

Leadership & Performance management

Level

From 2018 to 2028

Federal
USD 80M

State
USD 180M

C&E approach

Supply side

Demand side

As compared to ~80m invested in HSS since 2001
Gavi’s potential state level focus – will be dynamic through the transition period

- Focus on States with low performance, high # under-immunised children, identified funding gaps and political will
- Approach factors in existing donor presence
- In some States, Gavi will focus on strengthening overall RI programme, in coordination with other partners
- In other States, with high under-immunised number of children but relatively good coverage, a more targeted approach - to be developed based on further analysis
Gavi will have a new way of working at the state and national levels

Gavi’s new way of working in Nigeria to focus on

• Effective coordination at national & state levels

• Identification of complementarities and synergies with donors / partners

• Alignment and harmonisation, where possible

Accountability of each partner will be critical for success

Board meeting
6-7 June 2018
Risk mitigation strategies integral part of Gavi’s approach

<table>
<thead>
<tr>
<th>Key risks</th>
<th>Proposed mitigations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Elections in Feb, 2019</strong> (at federal and state levels)</td>
<td>• Gavi to follow expenditure closely</td>
</tr>
<tr>
<td></td>
<td>• Focus on essential activities</td>
</tr>
<tr>
<td></td>
<td>• Ensure budget for 2018-2019 fully includes committed amounts</td>
</tr>
<tr>
<td><strong>Risk of financial misuse</strong> (at federal and state levels)</td>
<td>• No cash to go through government</td>
</tr>
<tr>
<td></td>
<td>• Hybrid approach, capacity strengthening efforts</td>
</tr>
<tr>
<td><strong>Operational risks</strong> (incl. availability of operational funds, poor vaccine management, data falsification, etc.)</td>
<td>• Close monitoring of implementation, incl. joint quarterly review at federal and state levels</td>
</tr>
<tr>
<td></td>
<td>• HSS funding focused on reducing vaccine wastage, effective vaccine management, affecting behaviour change</td>
</tr>
<tr>
<td></td>
<td>• Gavi to also fund technical support</td>
</tr>
<tr>
<td></td>
<td>• Involvement of humanitarian agencies in insecure areas</td>
</tr>
</tbody>
</table>
Country expected to meet certain conditions to demonstrate progress

<table>
<thead>
<tr>
<th>Conditions based on Gavi policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Reimbursement of misused funds</td>
</tr>
<tr>
<td>• Continued timely co-financing of vaccines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional conditions (indicators to be developed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Increased domestically-financed health sector expenditures</td>
</tr>
<tr>
<td>• Achieving coverage targets for Penta3</td>
</tr>
<tr>
<td>• Progressive reduction in (non-justifiable) vaccine wastage rates</td>
</tr>
<tr>
<td>• Increased availability of vaccines and better visibility of vaccines at ward level</td>
</tr>
<tr>
<td>• Enhanced reliability of admin. data and reduced discrepancies vis-à-vis independent estimates</td>
</tr>
<tr>
<td>• Reduction in drop-out rates</td>
</tr>
<tr>
<td>• Increase managerial and financial capacity at federal and state level</td>
</tr>
</tbody>
</table>
Funding will be based on progress upon agreed milestones

Country’s progress will be monitored with the following approach…

1. **Semi-annual** technical review through ICC

2. **Annual** high-level review with senior leadership from FGoN and Gavi Alliance

3. **Mid-term review** in 2022-23 to discuss continuation / reduction of support

Funding decisions, including introduction of new vaccines based on demonstrated progress as per agreed metrics and timelines
Recommendation (1/3)

The Gavi Alliance Programme and Policy recommends to the Gavi Alliance Board that it:

a) **Approve** that Nigeria be exceptionally granted an extension of the country’s “Accelerated Transition” period (Phase 2) from 2021 to 2028 to align with its “National Strategy for Immunisation and PHC System Strategy 2018-2028” (NSIPSS) and that its HSS ceiling be increased to US$ 260 million for the 2018-2028 period;

b) **Note** that the indicative total cost of Gavi support to the NSIPSS is estimated to be an amount of up to US$ 1,033 million, including an indicative allocation of vaccines (US$ 773 million) and cash support (US$ 260 million), of which US$ 575 million is incremental to amounts previously forecasted for Nigeria;
Recommendation (1/3)

c) **Request** the Secretariat and Alliance partners, in consultation with the government, to develop an accountability framework **by November 2018**, based on section 2.7 of Doc 05 which takes into account the input from the Programme and Policy Committee; and to organise annually a high level review with Alliance leadership and senior government officials that assesses progress against the accountability framework and which will inform Gavi’s decision on support during the following year;

d) **Emphasise** that Gavi support to the NSIPSS is contingent on Nigeria fulfilling its financial and programmatic commitments under the NSIPSS and meeting the conditions set forth in the aforementioned accountability framework; and
Recommendation (1/3)

e) **Request** the Secretariat to provide annual updates to the PPC and Board, and conduct a comprehensive mid-term review in 2022-2023 on the progress of Gavi’s support to Nigeria to be presented to the PPC and Board.
THANK YOU